NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

WVE

Wave Life Sciences Ltd

Jul 02 • 04:00PM ET

6.75

Dollar change +0.24
Percentage change 3.61	%

Healthcare • Biotechnology • Singapore • NASD

Peers: IONS ALNY SRPT ARWR MRNA NBIX VRTX BIIB QURE EDIT

| Held by: IWM VXF IWO IBB SCHA VTWO IHE XPH VHT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.84	Insider Own	20.12%	Shs Outstand	154.09M	Perf Week	-1.46%
Market Cap	1.05B	Forward P/E	-	EPS next Y	-1.08	Insider Trans	-0.66%	Shs Float	124.26M	Perf Month	8.00%
Enterprise Value	838.45M	PEG	-	EPS next Q	-0.27	Inst Own	80.71%	Short Float	11.98%	Perf Quarter	-12.79%
Income	-112.33M	P/S	10.01	EPS this Y	-52.22%	Inst Trans	3.10%	Short Ratio	10.55	Perf Half Y	-47.67%
Sales	104.94M	P/B	6.05	EPS next Y	-1.52%	ROA	-42.90%	Short Interest	14.88M	Perf YTD	-45.43%
Book/sh	1.11	P/C	4.32	EPS next 5Y	-0.22%	ROE	-105.50%	52W High	16.74 -59.67%	Perf Year	35.27%
Cash/sh	1.56	P/FCF	-	EPS past 3/5Y	33.25% 34.27%	ROIC	-57.49%	52W Low	5.04 33.93%	Perf 3Y	153.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	38.28% 46.62%	Gross Margin	91.76%	Volatility	5.81% 5.99%	Perf 5Y	-39.35%
Dividend TTM	-	EV/Sales	7.99	EPS Y/Y TTM	-57.17%	Oper. Margin	-119.83%	ATR (14)	0.41	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.95	Sales Y/Y TTM	-7.06%	Profit Margin	-107.04%	RSI (14)	50.08	Recom	1.23
Dividend Gr. 3/5Y	- -	Current Ratio	2.95	EPS Q/Q	-18.15%	SMA20	-1.66%	Beta	-0.97	Target Price	20.38
Payout	-	Debt/Eq	0.13	Sales Q/Q	-26.82%	SMA50	0.48%	Rel Volume	0.67	Prev Close	6.51
Employees	288	LT Debt/Eq	0.09	Earnings	May 08 BMO	SMA200	-33.00%	Avg Volume	1.41M	Price	6.75
IPO	Nov 11, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.75% -23.04%	Trades		Volume	947,966	Change	3.61%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-11-25	Resumed	Raymond James	Outperform	$14
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$10
Apr-08-25	Initiated	Wedbush	Outperform	$18
Feb-25-25	Initiated	Jefferies	Buy	$26
Oct-16-24	Upgrade	Raymond James	Outperform → Strong Buy	$22
Sep-27-24	Resumed	JP Morgan	Overweight	$10 → $13
Sep-19-24	Initiated	B. Riley Securities	Buy	$11
Sep-09-24	Initiated	JP Morgan	Overweight	$10
May-15-24	Initiated	Wells Fargo	Overweight	$11
Dec-19-23	Upgrade	Leerink Partners	Market Perform → Outperform	$5 → $12
Jul-05-23	Initiated	Raymond James	Outperform	$7
May-24-23	Downgrade	Jefferies	Buy → Hold	$7 → $5
Dec-15-20	Resumed	H.C. Wainwright	Buy	$20
Oct-23-20	Initiated	RBC Capital Mkts	Sector Perform	$13
Dec-31-19	Downgrade	SVB Leerink	Outperform → Mkt Perform	$33 → $10
Nov-01-19	Initiated	Guggenheim	Buy	$43
Jul-15-19	Initiated	Cowen	Market Perform
Apr-17-19	Reiterated	H.C. Wainwright	Buy	$49 → $33
Aug-07-18	Initiated	Stifel	Buy	$56
Jul-23-18	Initiated	H.C. Wainwright	Buy	$49

Show Previous Ratings

Jun-20-25 04:01PM	Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions (GlobeNewswire) +5.94%
Jun-11-25 09:45AM	Raymond James bullish on biotech firms on favorable valuation (Investing.com)
May-29-25 08:30AM	Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-25 08:00AM	Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer (GlobeNewswire)
May-13-25 08:45AM	Is Wave Life Sciences (WVE) the Best Low Priced Biotech Stock to Buy Now? (Insider Monkey)
03:18AM	Loading…
May-09-25 03:18AM	WAVE Life Sciences Ltd (WVE) Q1 2025 Earnings Call Highlights: Clinical Advancements and ... (GuruFocus.com)
May-08-25 08:50AM	Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:45AM	Wave Life Sciences: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-07-25 12:45PM	Wave Life Sciences Q1 2025 Earnings Preview (Seeking Alpha)
10:25AM	WAVE Life Sciences Ltd (WVE) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
08:30AM	Geron (GERN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-06-25 05:35PM	Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -17.08%
May-01-25 10:01AM	Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:30AM	Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025 (GlobeNewswire)
09:03AM	Loading…
Mar-31-25 09:03AM	The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics (Zacks) -6.26%
Mar-28-25 09:39AM	Promising Genomics & Synthetic Biology Stocks to Consider in 2025 (Zacks)
09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-27-25 03:54PM	Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531 (SeekingAlpha) -10.08%
09:05AM	Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531 (Clinical Trials Arena)
05:35AM	Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar? (Zacks)
Mar-26-25 07:30AM	Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531 (GlobeNewswire) +6.14%
07:25AM	Wave to seek approval of Duchenne drug after mid-stage study data (BioPharma Dive)
Mar-20-25 09:28AM	Adma Biologics (ADMA) Surges 10.2%: Is This an Indication of Further Gains? (Zacks)
Mar-05-25 02:05AM	WAVE Life Sciences Ltd (WVE) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Clinical ... (GuruFocus.com) -5.88%
Mar-04-25 07:52AM	Wave Life Sciences: Q4 Earnings Snapshot (Associated Press Finance) +11.74%
07:30AM	Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-03-25 07:09AM	Earnings To Watch: WAVE Life Sciences Ltd (WVE) Reports Q4 2024 Result (GuruFocus.com)
Feb-25-25 08:30AM	Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025 (GlobeNewswire)
Feb-19-25 09:43AM	What Makes Wave Life Sciences Ltd. (WVE) an Investment Bet? (Insider Monkey)
08:30AM	Loading…
Feb-06-25 08:30AM	Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity (GlobeNewswire)
Jan-13-25 04:31PM	Is Wave Life Sciences (WVE) the Top Small Cap Stock to Buy with the Highest Upside Potential? (Insider Monkey)
09:00AM	Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation (GlobeNewswire)
Jan-09-25 05:10PM	Is Wave Life Sciences Ltd. (WVE) the Best Growth Stock to Buy Now Under $25? (Insider Monkey)
Dec-23-24 08:30AM	Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity (GlobeNewswire)
Dec-16-24 08:30AM	Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-26-24 08:30AM	Wave Life Sciences to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-15-24 08:30AM	Wave Life Sciences to Present at Jefferies London Healthcare Conference (GlobeNewswire) -8.87%
Nov-13-24 02:08AM	WAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-12-24 09:00AM	Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:58AM	Wave Life Sciences: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 07:08AM	WAVE Life Sciences Ltd (WVE) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Nov-05-24 10:00AM	Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Nov-04-24 04:05PM	Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024 (GlobeNewswire)
Oct-30-24 04:45PM	Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs (GlobeNewswire)
Oct-29-24 05:47PM	How to play biotech stocks: Insmed and Wave Life Sciences (Yahoo Finance Video)
Oct-28-24 09:55AM	Wall Street Analysts Predict a 34.53% Upside in Wave Life Sciences (WVE): Here's What You Should Know (Zacks)
Oct-24-24 05:53AM	1 Brand-New Big Reason to Buy This Biotech Stock Right Now (Motley Fool)
Oct-23-24 12:00PM	What Makes Wave Life Sciences (WVE) a Strong Momentum Stock: Buy Now? (Zacks)
Oct-21-24 04:15PM	Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. (Investor's Business Daily)
Oct-17-24 10:56AM	Wave Life Sciences Shares Surge After RNA Editing Discovery (GuruFocus.com)
07:33AM	Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last? (Zacks)
Oct-16-24 04:20PM	Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed. (Investor's Business Daily) +74.07%
04:13PM	RNA-Editing Stocks Soar by Record on Wave Lifes Trial Data (Bloomberg)
01:16PM	Wave Life Sciences Stock Climbs on RNA Editing Progress (The Wall Street Journal)
08:44AM	Wave Life Sciences (WVE): Advancing Gene Therapy for Duchenne Muscular Dystrophy (Insider Monkey)
08:30AM	Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
08:25AM	Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024 (GlobeNewswire)
08:15AM	Wave sees RNA editing validation in early trial results (BioPharma Dive)
Oct-11-24 11:56AM	GSK Bought More Shares of Biotech Wave Life Sciences (Barrons.com)
09:55AM	How Much Upside is Left in Wave Life Sciences (WVE)? Wall Street Analysts Think 89.71% (Zacks)
Oct-09-24 05:36PM	WAVE Life Sciences Ltd (WVE) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com) +5.12%
Oct-03-24 08:15AM	Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics (Motley Fool)
Oct-01-24 09:20AM	Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Sep-30-24 08:30AM	Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-25-24 09:14PM	Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire) +10.01% -10.99%
06:32AM	Waves stock swells as it eyes approval following Phase II DMD victory (Clinical Trials Arena)
Sep-24-24 04:01PM	Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire) +53.37%
11:19AM	Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug (Benzinga)
07:30AM	Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping (GlobeNewswire)
Aug-24-24 01:17AM	Insider Selling: President and CEO Paul Bolno Sells 48,366 Shares of WAVE Life Sciences Ltd (WVE) (GuruFocus.com)
Aug-12-24 08:30AM	Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-08-24 08:45AM	Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:47AM	Wave Life Sciences: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 08:30AM	Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024 (GlobeNewswire) -6.81%
Jun-25-24 07:30AM	Wave, with new data, plots path forward for Huntingtons drug (BioPharma Dive) -8.45%
07:30AM	Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington's Disease (GlobeNewswire)
Jun-12-24 08:30AM	Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing (GlobeNewswire)
May-30-24 08:30AM	Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-24 07:16AM	Wells Fargo Starts WAVE Life Sciences With Overweight Rating, $11 Price Target (MT Newswires)
May-10-24 04:53PM	Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2024 Earnings Call Transcript (Insider Monkey)
02:39PM	WAVE Life Sciences Reports First Quarter 2024 Financial Results (GuruFocus.com)
May-09-24 07:45AM	Wave Life Sciences: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer (GlobeNewswire)
May-07-24 08:30AM	Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-02-24 08:30AM	Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024 (GlobeNewswire)
Apr-30-24 08:30AM	Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Apr-23-24 08:30AM	Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing (GlobeNewswire)
Mar-27-24 08:30AM	Wave Life Sciences to Present at Upcoming Investor Conferences (GlobeNewswire) +6.71%
Mar-15-24 08:18AM	Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks (Insider Monkey)
Mar-07-24 10:47AM	Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2023 Earnings Call Transcript (Insider Monkey) +8.43%
Mar-06-24 12:51PM	WVE Stock Earnings: WAVE Life Sciences Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +31.32%
07:51AM	Wave Life Sciences: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 08:30AM	Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024 (GlobeNewswire)
04:16AM	Wave Life Sciences (WVE) Surges 10.9%: Is This an Indication of Further Gains? (Zacks)
Feb-27-24 08:30AM	Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy (GlobeNewswire) +10.87%

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Verdine Gregory L.	Director	Jun 13 '25	Sale	6.95	30,000	208,500	282,517	Jun 13 08:00 PM
GREGORY VERDINE	Director	Jun 13 '25	Proposed Sale	7.20	30,000	216,000		Jun 13 04:44 PM
HENRY CHRISTIAN O	Director	Mar 20 '25	Option Exercise	9.13	10,500	95,865	26,615	Mar 21 09:00 PM
HENRY CHRISTIAN O	Director	Mar 20 '25	Sale	9.77	10,500	102,574	16,115	Mar 21 09:00 PM
Christian Henry	Director	Mar 20 '25	Proposed Sale	9.77	10,500	102,579		Mar 20 04:03 PM
BOLNO PAUL	President and CEO	Mar 07 '25	Option Exercise	2.48	169,025	419,182	507,376	Mar 07 09:05 PM
BOLNO PAUL	President and CEO	Mar 07 '25	Sale	9.57	169,025	1,617,569	338,351	Mar 07 09:05 PM
Verdine Gregory L.	Director	Mar 07 '25	Option Exercise	2.48	133,402	330,837	312,517	Mar 07 09:00 PM
Verdine Gregory L.	Director	Mar 05 '25	Option Exercise	2.48	133,000	329,840	179,155	Mar 07 09:00 PM
PAUL BOLNO	Officer	Mar 07 '25	Proposed Sale	9.57	169,025	1,618,228		Mar 07 05:10 PM
Vargeese Chandra	See Remarks	Mar 04 '25	Option Exercise	2.48	91,754	227,550	362,687	Mar 05 05:14 PM
Vargeese Chandra	See Remarks	Jan 23 '25	Option Exercise	2.48	46,000	114,080	233,933	Jan 24 05:30 PM
BOLNO PAUL	President and CEO	Nov 25 '24	Option Exercise	2.48	50,000	124,000	267,351	Nov 27 09:00 PM
BOLNO PAUL	President and CEO	Nov 25 '24	Sale	15.00	50,000	750,000	217,351	Nov 27 09:00 PM
PAUL BOLNO	Officer	Nov 25 '24	Proposed Sale	15.00	50,000	750,000		Nov 25 05:09 PM
BOLNO PAUL	President and CEO	Nov 15 '24	Sale	14.32	51,234	733,671	217,351	Nov 15 09:00 PM
PAUL BOLNO	Officer	Nov 15 '24	Proposed Sale	14.32	51,234	733,743		Nov 15 04:16 PM
Francis Chris	See Remarks	Nov 08 '24	Option Exercise	8.17	36,000	294,120	36,000	Nov 13 08:00 PM
Francis Chris	See Remarks	Nov 08 '24	Sale	16.00	36,000	576,000	0	Nov 13 08:00 PM
CHRISTOPHER FRANCIS	Officer	Nov 08 '24	Proposed Sale	16.00	36,000	576,000		Nov 08 04:14 PM
Francis Chris	See Remarks	Oct 16 '24	Option Exercise	2.88	129,122	371,410	65,625	Oct 18 08:00 PM
Francis Chris	See Remarks	Oct 16 '24	Sale	13.67	208,836	2,855,051	0	Oct 18 08:00 PM
BOLNO PAUL	President and CEO	Oct 16 '24	Sale	15.00	90,474	1,357,110	268,585	Oct 18 08:00 PM
CHRISTOPHER FRANCIS	Officer	Oct 16 '24	Proposed Sale	13.67	208,836	2,855,051		Oct 16 04:19 PM
PAUL BOLNO	Officer	Oct 16 '24	Proposed Sale	15.00	90,474	1,357,110		Oct 16 04:13 PM
Moran Kyle	Chief Financial Officer	Oct 11 '24	Option Exercise	2.48	25,000	62,000	44,777	Oct 11 08:00 PM
GSK plc	10% Owner	Sep 27 '24	Buy	8.00	2,791,930	22,335,440	16,775,691	Oct 01 05:54 PM
Moran Kyle	Chief Financial Officer	Sep 25 '24	Sale	9.00	17,146	154,314	19,777	Sep 27 08:00 PM
KYLE MORAN	Officer	Sep 25 '24	Proposed Sale	9.00	17,146	154,314		Sep 25 09:40 PM
BOLNO PAUL	President and CEO	Aug 21 '24	Sale	5.78	48,366	279,555	359,059	Aug 23 06:00 PM
PAUL BOLNO	Officer	Aug 21 '24	Proposed Sale	5.78	48,366	279,638		Aug 21 04:24 PM
Vargeese Chandra	See Remarks	Jul 22 '24	Option Exercise	2.48	68,210	169,161	185,061	Jul 24 05:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

WVE

Wave Life Sciences Ltd

Upgrade your FINVIZ experience